BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 12866577)

  • 21. Molecular-cytogenetic analysis of HER-2/neu gene in BRCA1-associated breast cancers.
    Grushko TA; Blackwood MA; Schumm PL; Hagos FG; Adeyanju MO; Feldman MD; Sanders MO; Weber BL; Olopade OI
    Cancer Res; 2002 Mar; 62(5):1481-8. PubMed ID: 11888924
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overexpression of c-erbB-2 oncoprotein in muscle-invasive bladder carcinoma: relationship with gene amplification, clinicopathological parameters and prognostic outcome.
    Krüger S; Weitsch G; Büttner H; Matthiensen A; Böhmer T; Marquardt T; Sayk F; Feller AC; Böhle A
    Int J Oncol; 2002 Nov; 21(5):981-7. PubMed ID: 12370744
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients.
    Morrison C; Zanagnolo V; Ramirez N; Cohn DE; Kelbick N; Copeland L; Maxwell GL; Fowler JM
    J Clin Oncol; 2006 May; 24(15):2376-85. PubMed ID: 16710036
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization.
    Perez EA; Roche PC; Jenkins RB; Reynolds CA; Halling KC; Ingle JN; Wold LE
    Mayo Clin Proc; 2002 Feb; 77(2):148-54. PubMed ID: 11838648
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Expression of Her2/neu in locally advanced bladder cancer: implication for a molecular targeted therapy].
    Wülfing C; von Struensee D; Bierer S; Bögemann M; Hertle L; Eltze E
    Aktuelle Urol; 2005 Sep; 36(5):423-9. PubMed ID: 16163605
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HER-2/neu protein overexpression and gene amplification in human transitional cell carcinoma of the bladder.
    Coogan CL; Estrada CR; Kapur S; Bloom KJ
    Urology; 2004 Apr; 63(4):786-90. PubMed ID: 15072912
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer.
    Press MF; Finn RS; Cameron D; Di Leo A; Geyer CE; Villalobos IE; Santiago A; Guzman R; Gasparyan A; Ma Y; Danenberg K; Martin AM; Williams L; Oliva C; Stein S; Gagnon R; Arbushites M; Koehler MT
    Clin Cancer Res; 2008 Dec; 14(23):7861-70. PubMed ID: 19047115
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of polysomy 17 in transitional cell carcinoma of the bladder: immunohistochemical study of HER2/neu expression and fish analysis of c-erbB-2 gene and chromosome 17.
    Simonetti S; Russo R; Ciancia G; Altieri V; De Rosa G; Insabato L
    Int J Surg Pathol; 2009 Jun; 17(3):198-205. PubMed ID: 19443884
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of chromosome 17 polysomy on HER-2/neu status in breast cancer.
    Hyun CL; Lee HE; Kim KS; Kim SW; Kim JH; Choe G; Park SY
    J Clin Pathol; 2008 Mar; 61(3):317-21. PubMed ID: 17761736
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of aneusomy level and HER-2 gene copy number and their effect on amplification rate in breast cancer specimens read as 2+ in immunohistochemical analysis.
    Merola R; Mottolese M; Orlandi G; Vico E; Cognetti F; Sperduti I; Fabi A; Vitelli G; Cianciulli AM
    Eur J Cancer; 2006 Jul; 42(10):1501-6. PubMed ID: 16762541
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma.
    Gong Y; Booser DJ; Sneige N
    Cancer; 2005 May; 103(9):1763-9. PubMed ID: 15786420
    [TBL] [Abstract][Full Text] [Related]  

  • 32. EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma.
    Livasy CA; Reading FC; Moore DT; Boggess JF; Lininger RA
    Gynecol Oncol; 2006 Jan; 100(1):101-6. PubMed ID: 16157366
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fluorescence in situ hybridization and immunohistochemical analysis of p53 expression in endometrial cancer: prognostic value and relation to ploidy.
    Graesslin O; Chantot-Bastaraud S; Lorenzato M; Birembaut P; Quéreux C; Daraï E
    Ann Surg Oncol; 2008 Feb; 15(2):484-92. PubMed ID: 18071824
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Her-2/neu in barrett esophagus: a comparative study between histology, immunohistochemistry, and fluorescence in situ hybridization.
    Rossi E; Villanacci V; Bassotti G; Casa DD; Missale G; Minelli L; Cestari R
    Diagn Mol Pathol; 2006 Sep; 15(3):125-30. PubMed ID: 16932066
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fluorescence in situ hybridization analysis of HER-2/neu, c-myc, and p53 in endometrial cancer.
    Williams JA; Wang ZR; Parrish RS; Hazlett LJ; Smith ST; Young SR
    Exp Mol Pathol; 1999 Dec; 67(3):135-43. PubMed ID: 10600396
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rates of topoisomerase II-alpha and HER-2 gene amplification and expression in epithelial ovarian carcinoma.
    Mano MS; Awada A; Di Leo A; Durbecq V; Paesmans M; Cardoso F; Larsimont D; Piccart M
    Gynecol Oncol; 2004 Mar; 92(3):887-95. PubMed ID: 14984957
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fluorescence in situ hybridization study of HER-2/neu oncogene amplification in prostate cancer.
    Mark HF; Feldman D; Das S; Kye H; Mark S; Sun CL; Samy M
    Exp Mol Pathol; 1999 Jun; 66(2):170-8. PubMed ID: 10409446
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Algorithm for the diagnosis of HER-2/neu status in breast-infiltrating carcinomas.
    Falo C; Moreno A; Lloveras B; Figueras A; Varela M; Escobedo A
    Am J Clin Oncol; 2003 Oct; 26(5):465-70. PubMed ID: 14528071
    [TBL] [Abstract][Full Text] [Related]  

  • 39. AQUA and FISH analysis of HER-2/neu expression and amplification in a small cell lung carcinoma tissue microarray.
    Giltnane JM; Murren JR; Rimm DL; King BL
    Histopathology; 2006 Aug; 49(2):161-9. PubMed ID: 16879393
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: a single-institution experience of 2,279 cases and comparison of dual-color and single-color scoring.
    Lal P; Salazar PA; Hudis CA; Ladanyi M; Chen B
    Am J Clin Pathol; 2004 May; 121(5):631-6. PubMed ID: 15151202
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.